DCM
MCRB icon

Delpha Capital Management’s Seres Therapeutics MCRB Stock Holding History

Delpha Capital Management’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-46
Closed -$9K – 765
2017
Q4 		$9K Buy
+46
New +$9.45K 0.01% 1110

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Delpha Capital Management's MCRB Position: Q1 2018 in Review

Delpha Capital Management sold out of Seres Therapeutics (MCRB) in Q1 2018, closing a stake of 46 shares — an estimated $9K sold.

Delpha Capital Management first reported a position in MCRB in Q4 2017 and held it in 1 quarter. The position peaked at $9K in Q4 2017. 80 funds tracked by Wall St. Rank hold MCRB as of Q1 2018.

  • Delpha Capital Management reported no remaining Seres Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Delpha Capital Management sold 46 Seres Therapeutics shares in Q1 2018, an estimated $9K.
  • Delpha Capital Management first reported a position in Seres Therapeutics in Q4 2017 and held it in 1 quarter.
  • Delpha Capital Management's Seres Therapeutics position peaked at $9K in Q4 2017.
  • 80 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2018.

Based on Delpha Capital Management's 13F filing for Q1 2018, filed 11 May 2018.